X0508 4 2024-01-26 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001779458 Jones David Scott C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 false true false false SVP & Chief Commercial Officer true Common Stock 2024-01-26 4 M false 9604.00 12.90 A 47566.00 D Common Stock 2024-01-26 4 M false 16413.00 3.26 A 63979.00 D Common Stock 2024-01-26 4 S false 16413.00 25.4465 D 47566.00 D Common Stock 2024-01-26 4 S false 9604.00 25.2725 D 37962.00 D Stock Option (Right to Buy) 12.90 2024-01-26 4 M false 9604.00 0.00 D 2030-02-28 Common Stock 9604.00 8721.00 D Stock Option (Right to Buy) 3.26 2024-01-26 4 M false 16413.00 0.00 D 2033-01-05 Common Stock 16413.00 68742.00 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $26.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020 The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years. /s/ Ron Honig, Attorney-in-Fact 2024-01-29